Lundbeck has unveiled promising early-stage clinical data for its investigational therapy asedebart, highlighting a potential new treatment approach for patients living with Cushing’s disease, a rare endocrine disorder driven by excessive cortisol production. The findings were presented at the ENDO 2026 Annual Meeting in Chicago.
Asedebart is a monoclonal antibody designed to directly neutralize adrenocorticotropic hormone (ACTH), the hormone responsible for stimulating cortisol production in patients with Cushing’s disease. By targeting ACTH itself, the therapy aims to address the root cause of the disorder rather than simply controlling cortisol levels.
The preliminary Phase II Part A results showed that 7 of 8 evaluable patients achieved normalization of urinary free cortisol (UFC), a key marker used to measure disease activity and treatment response in Cushing’s disease. UFC normalization is considered clinically important because prolonged exposure to elevated cortisol levels is associated with serious complications, including cardiovascular disease, metabolic disorders, and reduced quality of life.
The study enrolled 12 patients, with participants receiving individualized intravenous doses of asedebart. Researchers reported that the treatment was generally well tolerated, with no unexpected safety concerns identified during the trial. While serious adverse events occurred in three patients, investigators noted that one reported death was unrelated to the study drug.
Lundbeck believes the results support further development of the therapy and plans to evaluate a more convenient subcutaneous formulation in the next phase of the study. The ongoing Part B trial will examine the safety, tolerability, pharmacokinetics, and effectiveness of subcutaneous administration.
Cushing’s disease remains an area of significant unmet medical need, as many patients do not achieve long-term remission following surgery or available medical treatments. If future studies confirm these early findings, asedebart could emerge as a novel targeted therapy offering a differentiated treatment option for patients with this challenging rare disease.
